Baltimore, MDNCT07053917Now EnrollingIRB Ready

Stroke Clinical Trial in Baltimore, MD

Access cutting-edge stroke treatment through this phase 1 clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.

Sponsored by Johns Hopkins University

Quick Self-Assessment

See if you qualify for this Baltimore location

Preparing your pre-screening questions…

Expert Care in Baltimore

Access stroke specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stroke treatment provided free

Apply for This Baltimore Location

Check if you qualify for this stroke clinical trial in Baltimore, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baltimore

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baltimore site if eligible
  4. 4Begin participation

About This Stroke Study in Baltimore

The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.

Sponsor: Johns Hopkins University

Who Can Participate

Inclusion Criteria

Over age 18 years, inclusive.
Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date
Ability to give informed consent and understand the tasks involved.
Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team
Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.
Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.
Are willing to be contacted via telephone for all necessary telephone contacts.
Must have a negative pregnancy test if able to bear children.
Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.
Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.
Are proficient in speaking and reading English.
Agree to have all clinical visit sessions recorded to audio and video.
Agree to not participate in any other interventional clinical trials during the duration of this study.

Exclusion Criteria

Taking one of the following medications in the 30 days prior to psilocybin administration:
selective serotonin reuptake inhibitor (SSRI)
Serotonin-norepinephrine reuptake inhibitors (SNRI)
Valproic acid
Carbamazepine.
tricyclic antidepressants
Monoamine Oxidase Inhibitors
Mirtazapine l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide
History of medically significant suicide attempt.
Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.
Systolic blood pressure that is greater than 150 mmHg systolic on \> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.
Diastolic blood pressure that is greater than 100 mmHg systolic on \> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.
Systolic blood pressure is less than 90 mmHg systolic on \> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.
Diastolic blood pressure is less than 30 mmHg systolic on \> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.
Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.
Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.
Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.
History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).
Social and/or personal circumstances that interfere with ability to perform follow up assessments.
Are pregnant or nursing.
Weigh less than 48 kg.
Are not able to give adequate informed consent.
Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder
Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.
Hypernatremia
Hypokalemia (but can have received repletion during the prior 24 hours)
Hyperkalemia
Glomerular filtration rate of \< 30 ml/min
Elevated of white blood cell count
Hemoglobin \< 7 g/dl
Platelet count \< 100,000 g/dl
Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.
Active suicidal ideation as assess by the C-SSRS.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT07053917) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stroke Treatment Options in Baltimore, MD

If you're searching for stroke treatment options in Baltimore, MD, this clinical trial (NCT07053917) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stroke clinical trials near you to find additional studies recruiting in your area.

More Stroke Trials in Baltimore, MD

See all stroke clinical trials recruiting in Baltimore — not just this study.

Browse Stroke Trials in Baltimore →

Browse More Trials by Condition

Stroke TrialsAll Conditions →

Ready to Join in Baltimore?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baltimore, MD